Psilocybin Therapy for Depression: What the Clinical Trials Actually Show
- Phil O'Zybyn
- 3 days ago
- 15 min read
Psilocybin Therapy for Depression: What the Clinical Trials Actually Show
From the first open-label feasibility studies in 2016 to two Phase 3 successes announced in 2025 and 2026, the clinical evidence for psilocybin in depression has moved faster than almost any psychiatric treatment in modern history. Here is what the research actually shows — and what remains genuinely uncertain.
Category: Research and Microdosing | /7-research-and-microdosing
Keywords: psilocybin therapy, psilocybin depression, psilocybin clinical trials, psilocybe mushrooms, mushroom education, mycology science, fungal biology, neuroplasticity, microdosing research, Canadian mycology, treatment-resistant depression, COMPASS psilocybin
Read time: ~13 minutes
Published by: Spores Lab | sporeslab.io
Research note: Spores Lab sells Psilocybe spore products for microscopy and taxonomic research purposes only. This blog discusses peer-reviewed clinical research on psilocybin. It does not constitute medical advice, and nothing here should be interpreted as encouraging illegal activity. Consult a qualified medical professional for any health-related decisions.
Psilocybin Therapy for Depression: What the Clinical Trials Actually Show
Depression is one of the most prevalent and treatment-resistant conditions in modern medicine. Approximately 30% of people with major depressive disorder do not respond adequately to two or more antidepressant medications — the clinical definition of treatment-resistant depression (TRD). For this population, the standard treatment options are limited, often poorly tolerated, and frequently temporary in their effects. The need for new therapeutic approaches is not a matter of preference. It is a public health imperative.
Against this backdrop, the clinical research programme around psilocybin therapy for depression stands as one of the most significant developments in psychiatry in decades. What began as a handful of open-label feasibility studies in the mid-2010s has, by 2026, produced two Phase 3 randomised controlled trial successes, multiple independent Phase 2 trials across three continents, and a meta-analytic evidence base that — with important caveats — points consistently in the same direction.
This blog covers the clinical trial evidence chronologically and honestly: what was found, in what populations, with what limitations, and what it means for the trajectory of psilocybin research. We draw directly on the primary published literature throughout.
The Starting Point: What Is Psilocybin Therapy?
Before examining the trial data, it is worth being precise about what psilocybin therapy is — because it differs meaningfully from conventional pharmacotherapy. In every clinical trial discussed here, psilocybin is administered not as a standalone pharmaceutical but within a structured therapeutic context: participants receive preparation sessions with trained therapists before dosing, supervised support throughout the dosing session (which lasts 4–6 hours), and integration sessions afterward to process the experience.
This is not an incidental detail. The therapeutic relationship, the quality of psychological preparation and support, and the set and setting of the dosing experience are considered by researchers to be active components of the treatment — not simply delivery mechanisms for the drug. The distinction matters when interpreting the trial results, particularly when comparing psilocybin to conventional antidepressants administered without this framework.
Psilocybin itself is the naturally occurring compound found in psilocybe mushrooms including Psilocybe cubensis and over 200 related species. In clinical trials, pharmaceutical-grade synthetic psilocybin is used — allowing precise, consistent dosing. The compound acts primarily as a serotonin 2A receptor agonist in the human brain, producing the acute neurological changes — increased brain entropy, disruption of the default mode network, decreased brain network modularity — that Spores Lab has covered in depth in the Research and Microdosing pillar.
2016–2018: The Feasibility Studies That Started Everything
The modern clinical research programme for psilocybin in depression is generally dated to two landmark open-label feasibility studies, both from Imperial College London.
Carhart-Harris et al. (2016), Lancet Psychiatry: The first study to examine psilocybin in patients with treatment-resistant depression. Twelve participants with TRD who had failed at least two antidepressant treatments received two sessions of psilocybin (10 mg and 25 mg, one week apart) alongside psychological support. At one week after the high-dose session, all 12 participants showed marked reductions in depression scores. At three months, 58% had maintained a treatment response. These were striking findings — but the study was open-label, had no control group, and enrolled only 12 participants. The researchers were explicit: this was a feasibility study, not a definitive demonstration of efficacy.
Carhart-Harris et al. (2018), Psychopharmacology: A six-month follow-up of the same 12 participants. Of the original cohort, 42% remained in remission at six months. No serious adverse events were attributed to the psilocybin. The durability of response — in a population for whom other treatments had failed — was the most significant signal.
These studies did not prove that psilocybin therapy works for depression. They demonstrated that it was feasible to conduct such research, that the safety profile appeared acceptable, and that the effect sizes were large enough to justify larger controlled trials. That is precisely what they claimed to show — and they were right.
2021: The NEJM Trials Change the Picture
Two randomised controlled trials published in the New England Journal of Medicine in 2021 represented a step change in the evidence base.
Carhart-Harris et al. (2021): Psilocybin vs. Escitalopram
The first direct head-to-head comparison of psilocybin therapy against a front-line antidepressant. In this Phase 2 double-blind randomised controlled trial at Imperial College London, 59 patients with moderate-to-severe major depressive disorder (not treatment-resistant) were assigned to receive either two sessions of 25 mg psilocybin plus six weeks of daily oral placebo, or two sessions of 1 mg psilocybin (functionally a placebo dose) plus six weeks of daily oral escitalopram.
The primary outcome — change in the Quick Inventory of Depressive Symptomatology (QIDS-SR-16) score at six weeks — did not reach statistical significance between groups (a difference of 2.0 points, p = 0.17). However, secondary outcomes consistently favoured psilocybin: remission rates were twice as high in the psilocybin group (57% vs 28%), and measures of anxiety, wellbeing, and emotional processing all showed greater improvement with psilocybin.
The authors interpreted this as psilocybin performing at least as well as escitalopram on the primary measure, with a more favourable profile on secondary outcomes. The study's limitations are important: 59 participants is a small sample, the blinding was imperfect (participants could generally tell which treatment they received), and the six-week timeframe is short. Larger, longer trials were the needed next step.
KEY FINDING: Psilocybin therapy was non-inferior to escitalopram on primary outcome. Remission rates twice as high in psilocybin group (57% vs 28%). Secondary outcomes consistently favoured psilocybin. Carhart-Harris et al., NEJM 2021.
Goodwin et al. (2022): The COMPASS Phase 2b Trial
The largest controlled psilocybin trial published to that point: 233 patients with treatment-resistant depression across 22 sites in 10 countries. Participants were randomly assigned to receive a single dose of 1 mg, 10 mg, or 25 mg psilocybin, with standardised psychological support. The primary outcome was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at three weeks.
The 25 mg dose produced a statistically significant reduction in MADRS scores compared to the 1 mg control (mean difference −6.6 points, 95% CI −10.2 to −2.9; p = 0.002). The 10 mg dose did not reach significance. Response rate at three weeks was 37% for the 25 mg group. The average duration of benefit from a single 25 mg dose was approximately 12 weeks.
These results were more modest than some earlier open-label studies suggested, which the researchers attributed to the more severely treatment-resistant population enrolled and the rigour of the controlled design. The study's most significant contribution was establishing a clear dose-response relationship — only 25 mg produced a meaningful effect — and generating the safety and efficacy data needed to proceed to Phase 3.
KEY FINDING: 25 mg psilocybin significantly reduced MADRS scores vs 1 mg control in 233 TRD patients. 37% response rate at 3 weeks. Average benefit duration ~12 weeks. Goodwin et al., NEJM 2022.
2021–2023: Independent Replication
The Imperial College and COMPASS results did not stand alone. Several independent research groups published supporting evidence across the same period.
Davis et al. (2021), JAMA Psychiatry: A randomised controlled trial at Johns Hopkins University in 24 patients with major depressive disorder. Immediate treatment with psilocybin-assisted therapy produced large, rapid, and sustained antidepressant effects compared to a delayed treatment control group, maintained at one-month follow-up. A long-term follow-up (Gukasyan et al., 2022) of the same participants found response and remission rates of 75% and 58% respectively at 12 months — the longest-term controlled outcome data published for psilocybin in depression at the time.
Raison et al. (2023), JAMA: A Phase 2 randomised clinical trial of single-dose psilocybin treatment for major depressive disorder involving 104 participants. Found significant reductions in depression scores at eight weeks for the psilocybin group. This was a notable trial because it was conducted without the intensive therapeutic support framework used in earlier studies — a more pragmatic design that, if replicated, would have significant implications for scalability.
The convergence of results across independent research groups, using different patient populations, outcome measures, and therapeutic frameworks, substantially strengthened the case for psilocybin therapy as a genuine antidepressant intervention rather than an artefact of specific trial conditions.
2025–2026: Phase 3 — A Historic Milestone
Phase 3 trials are the gold standard of clinical evidence: larger samples, stricter controls, and the threshold required for regulatory approval. COMPASS Pathways' COMP360 programme represents the first Phase 3 evaluation of any classical psychedelic for a psychiatric indication.
COMPASS Phase 3 Trial 1 (COMP005): June 2025
COMPASS announced in June 2025 that its first Phase 3 trial had met its primary endpoint with statistical significance (p < 0.001). The trial enrolled 258 patients with treatment-resistant depression and compared a single 25 mg dose of COMP360 against placebo (1 mg), with standardised psychological support. This was the first Phase 3 success for any classical psychedelic in a psychiatric indication — a milestone that had been anticipated but could not be assumed given the historical failure rate of Phase 3 psychiatric trials.
COMPASS Phase 3 Trial 2 (COMP006): February 2026
The second COMPASS Phase 3 trial, results disclosed February 17, 2026, reinforced the first. Key findings:
• Primary endpoint met: Single dose of COMP360 25 mg vs placebo produced a mean treatment difference of −3.6 MADRS points (95% CI [−5.7, −1.5]; p < 0.001) at week 6
• Clinically meaningful response: 25% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at week 6, with durability lasting through 26 weeks after one or two doses
• Second dose benefit: Over 40% of those who achieved a clinically meaningful reduction but had not remitted by 6 weeks went into remission after a second dose
• Rapid onset: Statistically significant improvement was apparent from the day following administration, maintained at all measured timepoints through week 6
• Safety: Most treatment-emergent adverse events occurred on the days of administration (66%), with the vast majority (88%) resolving within a day. Most common adverse events: headache, nausea, and visual hallucination. No clinically meaningful imbalance in suicidality between arms
COMPASS CEO noted that the 26-week data from COMP006 Part B is expected in early Q3 2026, which will provide the longest Phase 3 durability data yet published.
HISTORIC MILESTONE: Two Phase 3 trials of psilocybin for treatment-resistant depression met primary endpoints in 2025 and 2026 — the first Phase 3 successes for any classical psychedelic in psychiatry. COMPASS COMP360 programme.
The Meta-Analytic Picture
Alongside the individual trials, several systematic reviews and meta-analyses have aggregated the evidence.
A 2023 meta-analysis published in The Lancet covering 9 studies and 596 participants found a pooled standardised mean difference (SMD) of −0.78 favouring psilocybin over control on depression outcome measures — a medium-to-large effect size by conventional standards. A 2025 meta-analysis incorporating the more recent trial data reported effect sizes of Hedges' g = 0.66 to 0.91 across studies, with important caveats about heterogeneity in populations, dose schedules, and therapeutic support protocols.
Meta-analyses also consistently flag the limitations of the current evidence base: most trials have small samples, imperfect blinding (the subjective effects of psilocybin make it difficult for participants to be truly unaware of their treatment assignment), and high variability in the nature and intensity of the psychological support provided. These are genuine methodological constraints that the field acknowledges — and that the Phase 3 trials were specifically designed to address through larger samples and more standardised protocols.
How Does Psilocybin Compare to Existing Antidepressants?
This is the question most readers want answered — and it deserves an honest response rather than a marketing one.
Speed of onset: Conventional SSRIs and SNRIs typically require 4–6 weeks of daily dosing before meaningful antidepressant effects emerge. Psilocybin therapy produces measurable effects from the day after administration — a clinically significant difference for patients in acute distress.
Durability from single administration: A single 25 mg psilocybin session produces effects lasting weeks to months. The COMPASS Phase 2b data suggested an average duration of approximately 12 weeks from a single dose. The Johns Hopkins 12-month data showed 75% response rates with one or two sessions. No conventional antidepressant produces comparable durability from a single dose.
Response in treatment-resistant populations: Standard antidepressants, by definition, have failed the treatment-resistant populations enrolled in many psilocybin trials. The fact that psilocybin produces meaningful response rates in patients who have not responded to two or more adequate antidepressant courses is clinically important and does not have a direct conventional comparator.
Effect size: The meta-analytic effect sizes for psilocybin (Hedges' g = 0.66–0.91) compare favourably with those reported for SSRIs in meta-analyses (typically g = 0.30–0.50), though direct comparisons are complicated by different patient populations and trial designs.
What psilocybin is not: It is not a daily medication. It is not available outside a highly controlled therapeutic context. It requires significant time investment from participants (preparation, dosing, integration). It is not appropriate for everyone — contraindications include personal or family history of psychosis. And as the Carhart-Harris 2021 trial showed, the therapeutic support framework appears to be an active component of the treatment, not a passive delivery mechanism.
The Neurological Mechanism: Why It Works
Understanding why psilocybin produces antidepressant effects is an active area of research, and the mechanistic picture is becoming clearer. The evidence points to several converging processes:
Default mode network disruption: Depression is consistently associated with hyperactivity of the default mode network — the brain system involved in self-referential thinking, rumination, and the construction of a rigid, negative self-narrative. Psilocybin acutely disrupts DMN coherence, temporarily dissolving the rigid neural patterns that characterise depressive cognition. The Lyons et al. 2026 study found lasting decreases in brain network modularity — a more globally integrated, less siloed brain — correlating with improvements in well-being one month later.
Neuroplasticity: Preclinical research and the human DTI findings from Lyons et al. suggest that psilocybin promotes structural neuroplasticity — the formation of new neural connections — particularly in the prefrontal cortex. This may underpin the durability of response: a brain that has formed new connections is less likely to return immediately to its prior depressive patterns.
Psychological insight as mediator: The same 2026 study found that acute brain entropy predicts next-day psychological insight, which then predicts well-being improvements at one month. This suggests that the experience of psilocybin — the subjective process of gaining insight during the session — is mechanistically involved in producing the therapeutic effect, not just the pharmacology.
Increased cognitive flexibility: Doss et al. (2021) found that psilocybin therapy increased cognitive flexibility — the brain's ability to shift attention and update beliefs — in patients with major depressive disorder. Reduced cognitive flexibility is a core feature of depression; restoring it may be a key mechanism of therapeutic action.
The Canadian Research Context
For Canadian readers, the psilocybin research landscape has direct domestic relevance. Health Canada has granted exemptions under Section 56 of the Controlled Drugs and Substances Act for therapeutic psilocybin use since 2020, and the compound is now accessible through the Special Access Programme for patients with serious conditions. Several Canadian institutions are running active psilocybin research programmes:
• Unity Health Toronto has an active psilocybin for PTSD trial — one of the most advanced psychedelic trials currently running in Canada
• Sunnybrook Health Sciences Centre is running the EMBRACE neuroimaging trial, examining psilocybin's brain effects in a Canadian clinical population
• University of Toronto and McGill University both have active psychedelic research programmes with psilocybin components
Canada's regulatory framework — more permissive than the US (where psilocybin remains Schedule I federally) but more structured than jurisdictions where oversight is minimal — positions the country well for both research and, eventually, clinical implementation as the evidence base matures.
What the Evidence Does Not Yet Show
Honest coverage requires stating what the clinical trial evidence does not yet establish:
• Long-term safety at scale: Most trial participants have been followed for 12 months or less. The safety profile of repeated psilocybin sessions over years is not yet characterised at the population level
• Optimal dosing schedules: The evidence supports one or two sessions of 25 mg, but the optimal frequency, number of sessions, and re-treatment protocols for maintaining long-term response are not yet established
• Real-world effectiveness: Clinical trial populations are selected, monitored, and supported far more intensively than routine clinical practice. Effectiveness in real-world settings — where therapeutic support may be less intensive — remains to be demonstrated
• Comparison with other active interventions: The Carhart-Harris 2021 trial compared psilocybin to escitalopram, but psilocybin has not yet been directly compared to other first-line treatments such as CBT or combination pharmacotherapy in large trials
• Regulatory approval: As of mid-2026, psilocybin has not received regulatory approval as a medicine in Canada, the US, or the UK. The COMPASS Phase 3 data has been submitted to regulators; approval decisions are anticipated in 2026–2027
Explore the Full Research and Microdosing Pillar
This blog is part of Spores Lab's Research and Microdosing pillar. For deeper background on the neurological mechanisms discussed here — brain entropy, default mode network disruption, neuroplasticity, and network modularity — see the companion cluster blogs already published in this pillar. The full seven-pillar knowledge base at sporeslab.io covers Mushroom Growing Basics for foundational cultivation knowledge; Substrate Preparation and Contamination & Sterile Technique for clean, research-grade practice; Growing Environment for environmental control across psilocybe species; Mushroom Genetics & Strains for a deep dive into Psilocybe cubensis strain profiles and spore viability; Growing Equipment for laboratory-grade tool guidance; and Research and Microdosing for all science-forward content. Explore the full library at sporeslab.io/blog.
Key Conclusions: What the Evidence Establishes
1. The clinical evidence for psilocybin therapy in depression is now the strongest in the compound's research history. Two independent Phase 3 trials met primary endpoints in 2025 and 2026 — a historic first for classical psychedelics in psychiatry.
2. The effect sizes are clinically meaningful and larger than those typically reported for conventional antidepressants in comparable populations, particularly in treatment-resistant patients.
3. Onset is rapid and durability is exceptional. Effects are measurable from the day after a single session and can persist for 3–12 months after one or two doses — a profile that no conventional antidepressant matches.
4. The therapeutic support framework is an active component — not an optional add-on. Psilocybin therapy as studied in clinical trials is a structured intervention combining pharmacology with psychological preparation, support, and integration.
5. Important uncertainties remain. Long-term safety at scale, optimal dosing protocols, real-world effectiveness, and regulatory approval are all active frontiers. The evidence is strong enough to be taken seriously; it is not yet complete enough for unrestricted clinical roll-out.
6. Canada is a significant player in this research landscape. Active trials, an evolving regulatory framework, and institutional investment in psychedelic research make Canada a jurisdiction where these developments have direct practical relevance.
FAQ: Psilocybin Therapy for Depression
Q: Has psilocybin been approved as a treatment for depression?
Not yet, as of mid-2026. COMPASS Pathways has submitted its Phase 3 data to regulators, and approval decisions for COMP360 (pharmaceutical-grade synthetic psilocybin) are anticipated in the 2026–2027 timeframe in the US and UK. In Canada, Health Canada has not yet approved psilocybin as a medicine, but access is available for patients with serious conditions through the Special Access Programme. Regulatory approval, if granted, would apply to pharmaceutical-grade synthetic psilocybin administered in a controlled therapeutic context — not to mushroom-derived products.
Q: What is treatment-resistant depression and why does it matter for this research?
Treatment-resistant depression (TRD) is conventionally defined as depression that has not responded adequately to at least two different antidepressant treatments of adequate dose and duration. Approximately 30% of people with major depressive disorder meet this definition. TRD is associated with significantly greater disability, healthcare utilisation, and risk of suicide than responsive depression. Many of the key psilocybin trials — particularly the COMPASS programme — have specifically enrolled TRD populations, making the positive results particularly clinically significant.
Q: What does a psilocybin therapy session actually involve?
In clinical trials, a psilocybin therapy session typically involves one or more preparation meetings with trained therapists to set intentions and establish rapport, a dosing day in a calm clinical environment (dimly lit, comfortable, with music) lasting 4–6 hours during which the participant is supervised throughout, and one or more integration sessions afterward to process and contextualise the experience. The dose used in most effective trials is 25 mg of pharmaceutical-grade psilocybin. The therapeutic relationship and the quality of the supported experience are considered active components of the treatment by researchers.
Q: Is psilocybin therapy the same as taking magic mushrooms?
No, in several important respects. Clinical trials use pharmaceutical-grade synthetic psilocybin of known purity and precise dosage — not mushroom-derived material. The dosing occurs within a highly structured therapeutic context with trained professionals present throughout. The preparation and integration support provided in trials is intensive and evidence-informed. Consuming mushrooms outside this framework — without dosage control, professional support, or psychological preparation — is a fundamentally different experience with different risk and benefit profiles. The clinical research findings apply to the structured therapeutic intervention, not to unsupported recreational use.
Q: What are the main risks of psilocybin therapy?
The clinical trial safety data is generally reassuring. The most common adverse events in the COMPASS Phase 3 trials were headache, nausea, and visual hallucinations — predominantly occurring on the day of administration and resolving within a day. There was no clinically meaningful imbalance in suicidality between treatment and placebo arms. The most significant safety consideration is the risk of triggering or exacerbating psychotic episodes in people with personal or family history of psychosis — all published trials have excluded these participants. Psilocybin is not considered to be physiologically addictive. Psychological distress during the session ('challenging experiences') is common but appears to be manageable with professional support and does not predict poor therapeutic outcomes.
Q: Where can I read the primary research cited in this article?
All primary sources are publicly accessible via their DOIs. Key references: Carhart-Harris et al. (2016) Lancet Psychiatry; Carhart-Harris et al. (2021) N Engl J Med doi:10.1056/NEJMoa2032994; Goodwin et al. (2022) N Engl J Med doi:10.1056/NEJMoa2206443; Davis et al. (2021) JAMA Psychiatry; Gukasyan et al. (2022) 12-month follow-up; Raison et al. (2023) JAMA; COMPASS Pathways Phase 3 press releases June 2025 and February 2026. PubMed and Google Scholar provide access to most full texts.
Explore psilocybe genetics and research at Spores Lab.
Browse viability-tested Psilocybe cubensis spore products for microscopy and research at sporeslab.io/shop. Read the full Research and Microdosing pillar and all seven blog categories at sporeslab.io/blog.
Comments